Viemed Healthcare Announces Second Quarter 2025 Earnings Conference Call Details – Corpus Christi Caller-Times
| The content on this page was provided by an independent third party and syndicated by XPR Media. Members of the editorial and news staff of the USA TODAY Network were not involved in the creation of this content. |
Written by
viemed healthcare inc.
LAFAYETTE, LA / ACCESS Newswire / July 22, 2025 / Viemed Healthcare, Inc. (the “Company” or “Viemed“) (NASDAQ:VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, today announced that it will host its Second Quarter 2025 Earnings Conference Call on Thursday, August 7, 2025, at 11:00 a.m. EDT.
Interested parties may participate in the call by dialing:
(877) 407-6176 (US Toll-Free)
+1 (201) 689-8451 (International)
Live Audio Webcast:
Following the live call, a replay will be available in the Investor Relations section of the Company’s website at www.viemed.com.
ABOUT VIEMED HEALTHCARE, INC.
Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at www.viemed.com.
For further information, please contact:
Investor Relations
[email protected]
Tripp Sullivan
SCR Partners, LLC
615-942-7077
Trae Fitzgerald
Chief Financial Officer
Viemed Healthcare, Inc.
337-504-3802
SOURCE: Viemed Healthcare, Inc.
View the original press release on ACCESS Newswire
Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]
NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value
SHELTON, CONNECTICUT / ACCESS Newswire / July 23, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the “Company”), and a clinical stage,…
link
